欧洲幽门螺杆菌感染管理登记处（Hp-EuReg）：俄罗斯2360例接受一线治疗患者的分析

European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia.

作者信息

Bordin D S, Embutnieks Yu V, Vologzhanina L G, Il'chishina T A, Voinovan I N, Sarsenbaeva A S, Alekseenko S A, Zaitsev O V, Abdulkhakov R A, Osipenko M F, Livzan M A, Tsukanov V V, Burkov S G, Bakulina N V, Dekhnich N N, Tarasova L V, Plotnikova E Yu, Maev I V, Kucheryavyi Yu A, Baryshnikova N V, Butov M A, Kolbasnikov S V, Pakhomova A L, Zhestkova T V, Baranovskii A Yu, Abdulkhakov S R, Ageeva E A, Lyalyukova E A, Vasyutin A V, Golubev N N, Savilova I V, Morkovkina L V, Kononova A G, Megraud F, O'Morain C, Ramas M, Nyssen O P, McNicholl A G, Gisbert J P

机构信息

A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia.

Tver state medical University, Ministry of health of Russia, Tver, Russia.

出版信息

Ter Arkh. 2018 Feb 15;90(2):35-42. doi: 10.26442/terarkh201890235-42.

DOI:10.26442/terarkh201890235-42

PMID:30701770

Abstract

AIM

European Registry on the management of Helicobacter pylori infection («Hp-EuReg») - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations.

MATERIALS AND METHODS

The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy.

RESULTS

The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effec- tiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clar- ithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment.

CONCLUSION

Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.

摘要

目的

欧洲幽门螺杆菌感染管理注册研究（“Hp-EuReg”）——由欧洲幽门螺杆菌与微生物群研究组发起的一项多中心前瞻性观察性研究，在27个欧洲国家开展，旨在评估幽门螺杆菌诊断和治疗的实际临床实践及其与国际推荐的比较。

材料与方法

对2013年至2017年俄罗斯“Hp-EuReg”中心登记的2360例接受一线根除治疗的患者进行分析。

结果

幽门螺杆菌的主要诊断方法中，组织学检查（37.7%）、快速尿素酶试验（29.2%）和血清学检查（29.7%）最为常见。9.4%的病例根除治疗持续时间为7天，65.3%为10天，25.3%为14天。为控制治疗效果，采用了粪便幽门螺杆菌抗原检测（31.3%）、尿素呼气试验（23.4%）和组织学方法（23.3%）。3.6%的病例错误地使用了血清学检查。17.3%的患者未进行疗效监测。质子泵抑制剂、阿莫西林、克拉霉素三联疗法（按方案）的疗效在7天疗程时为67.6%，10天疗程时为81.1%，14天疗程时为86.7%。添加铋剂的三联疗法（按方案）在接受10天方案的组中根除率达到90.6%，在接受14天治疗的组中为93.6%。